Shanghai, China, May 12, 2026 --- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  ("Ribo", 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental service cooperation, combining the end-to-end R&D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's profound expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in the oligonucleotide drug R&D cycle.

Modern optical sensors passively collect data, which is then exported for analysis. Researchers at Texas A&M University are developing optical sensors that can compress and analyze their own data, saving time, money and energy.

Proteins change shape as they function, and these changes are essential for processes such as drug interactions and cellular activity. Researchers from the Tokyo University of Science developed an AI-based method called DeepAFM that is trained on millions of simulated images representing different protein states, accurately identifying transitions between closed and open states in a protein called SecA. This approach highlights the growing potential of AI to solve complex challenges in biology and medicine.

An early warning system for sepsis, one of the deadliest infections for hospital patients, has been approved for use by the FDA, one of the first AI-based medical tools to get clearance.

The tool, developed by Johns Hopkins University researchers and now commercialized by Bayesian Health, detects sepsis hours faster than doctors and has reduced deaths by nearly 20%.